Evaluation of the association of hand-foot syndrome with anticancer drugs using the US food and drug administration adverse event reporting system (FAERS) and Japanese adverse drug event report (JADER) databases

Yakugaku Zasshi

Volumn 136, Issue 3, 2016, Pages 507-515

  Sasaoka, Sayaka ^a   Matsui, Toshinobu ^a   Abe, Junko ^a,b   Umetsu, Ryogo ^c   Kato, Yamato ^a   Ueda, Natsumi ^a   Hane, Yuuki ^a   Motooka, Yumi ^a   Hatahira, Haruna ^a   Kinosada, Yasutomi ^d   Nakamura, Mitsuhiro ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b Medical Database Co   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d GIFU UNIVERSITY   (Japan)

Author keywords

Adverse event; Anticancer drug; Hand foot syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; REGORAFENIB; SORAFENIB;

CANCER CHEMOTHERAPY; DRUG INDUCED DISEASE; FACTUAL DATABASE; HAND FOOT SYNDROME; HUMAN; JAPANESE ADVERSE DRUG EVENT REPORT DATABASE; NOTE; ODDS RATIO; UNITED STATES FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOOD AND DRUG ADMINISTRATION; HAND-FOOT SYNDROME; INFORMATION PROCESSING; JAPAN; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; DATASETS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HAND-FOOT SYNDROME; HUMANS; JAPAN; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84959354890     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.15-00222     Document Type: Note

References (27)

1. Ministry of Health, Labour and Welfare, “Jutoku fukusayo shikkanbetsu taiou manual: Teashi syokogun.”: , Pharmaceuticals and Medical Devices Agency Web, cited 19 July, 2015.
2. Farr K. P., Safwat A., Case Rep. Oncol., 4, 229-235 (2011).
3. Morikawa K., Bull. Natl. Inst. Health Sci., 129, 1-26 (2011).
4. Fujita T., Jpn. J. Pharmacoepidemiol., 14, 27-36 (2009).
5. Umetsu R., Nishibata Y., Abe J., Suzuki Y., Hara H., Nagasawa H., Kinosada Y., Nakamura M., Yakugaku Zasshi, 134, 299-304 (2014).
6. Hirooka T., “PMDA fukusayou database no katsuyou 3 fukusayou hatsugen madeno hatsugen pattern niyoru bunrui-nissuu data ni tsuiteno riyou.”:, cited 19 July, 2015.
7. Yamada M., Handa A., Jpn. J. Pharmacoepidemiol., 19, 23-30 (2014).
8. Sauzet O., Carvajal A., Escudero A., Molokhia M., Cornelius V. R., Drug Saf., 36, 995-1006 (2013).
9. Scheithauer W., McKendrick J., Begbie S., Borner M., Burns W. I., Burris H. A., Cassidy J., Jodrell D., Koralewski P., Levine E. L., Marschner N., Maroun J., Garcia-Alfonso P., Tujakowski J., Van Hazel G., Wong A., Zaluski J., Twelves C., Ann. Oncol., 14, 1735-1743 (2003).
10. He, A. B., Peng, X. L., Song, J., Zhang, J. X., Dong, W. G., Luo, R. F., Tang, Y., World, J. Gastroenterol., 21, 4358-4364 (2015).
11. Kroep J. R., van Warkhoven E., Polee M., van Groeningen C. J., Beeker A., Erdkamp F., Weijl N., van Bochove A., Erjavec Z., Kapiteijin E., Stiggelbout A. M., Nortier H. W., Gelderblom H., J. Geriatr. Oncol., 6, 307-315 (2015).
12. Lipworth A. D., Robert C., Zhu A. X., Oncology, 77, 257-271 (2009).
13. Iijima M., Fukino K., Adachi M., Tsukamoto T., Murai M., Naito S., Minami H., Furuse J., Akaza H., J. Dermatol., 38, 261-266 (2011).
14. Yoshino T., Komatsu Y., Yamada Y., Yamazaki K., Tsuji A., Ura T., Grothey A., van Cutsem E., Wagner A., Cihon F., Hamada Y., Ohtsu A., Invest. New Drugs, 33, 740-750 (2015).
15. Bruix J., Tak W.-Y., Gasbarrini A., Santoro A., Colombo M., Lim H.-Y., Mazzaferro V., Wiest R., Reig M., Wagner A., Bolondi L., Eur. J. Cancer, 49, 3412-3419 (2013).
16. Sundriyal D., Kumar N., Oxf. Med. Case Reports, 2015, 206-207 (2015).
17. Milano G., Etienne-Grimaldi M. C., Mari M., Lassalle S., Formento J. L., Francoual M., Lacour J. P., Hofman P., Br. J. Clin. Pharmacol., 66, 88-95 (2008).
18. Lai S. E., Kuzel T., Lacouture M. E., J. Clin. Oncol., 25, 341-343 (2007).
19. Beldner M., Jacobson M., Burges G. E., Dewaay D., Maize J. C. Jr., Chaudhary U. B., Oncologist, 12, 1178-1182 (2007).
20. Carr M. E., South. Med. J., 97, 707-709 (2004).
21. Robert C., Soria J. C., Spatz A., Le Cesne A., Malka D., Pautier P., Wechsler J., Lhomme C., Escudier B., Boige V., Armand J. P., Le Chevalier T., Lancet Oncol., 6, 491-500 (2005).
22. Jacobi U., Waibler E., Schulze P., Sehouli J., Oskay-Ozcelik G., Schmook T., Sterry W., Lademann J., Ann. Oncol., 16, 1210-1211 (2005).
23. Jain A., Dubashi B., J. Pharmacol. Pharmacother., 3, 200-201 (2012).
24. Ueda N., Umetsu R., Abe J., Kato Y., Nakayama Y., Kato Z., Kinosada Y., Nakamura M., Biol. Pharm. Bull., 38, 1638-1644 (2015).
25. Abe J., Umetsu R., Kato Y., Ueda N., Nakayama Y., Suzuki Y., Suzuki T., Nagasawa H., Kinosada Y., Nakamura M., Int. J. Med. Sci., 12, 312-321 (2015).
26. Suzuki Y., Suzuki H., Umetsu R., Uranishi H., Abe J., Nishibata Y., Sekiya Y., Miyamura N., Hara H., Tsuchiya T., Kinosada Y., Nakamura M., Biol. Pharm. Bull., 38, 680-686 (2015).
27. Abe J., Mataki K., Umetsu R., Ueda N., Kato Y., Nakayama Y., Kinosada Y., Hara H., Inagaki N., Nakamura M., Allergol. Int., 64, 277-279 (2015).